NO982696L - Anvendelse av tricykliske derivater av 1,4-dihydro-1,4-diokso-1H-naftalen, nye oppnÕdde forbindelser og deres applikasjon i terapi - Google Patents

Anvendelse av tricykliske derivater av 1,4-dihydro-1,4-diokso-1H-naftalen, nye oppnÕdde forbindelser og deres applikasjon i terapi

Info

Publication number
NO982696L
NO982696L NO982696A NO982696A NO982696L NO 982696 L NO982696 L NO 982696L NO 982696 A NO982696 A NO 982696A NO 982696 A NO982696 A NO 982696A NO 982696 L NO982696 L NO 982696L
Authority
NO
Norway
Prior art keywords
substituted
atom
alkyl radical
radical
aromatic ring
Prior art date
Application number
NO982696A
Other languages
English (en)
Other versions
NO982696D0 (no
Inventor
Odile Boutherin-Falson
Stephanie Desquand-Billiald
Anita Favrou
Michel Finet
Olivier Tembo
Jean-Luc Torregrosa
Sylvie Yannic-Arnoult
Marquer Florence Domagala-Le
Original Assignee
Innothera Lab Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innothera Lab Sa filed Critical Innothera Lab Sa
Publication of NO982696D0 publication Critical patent/NO982696D0/no
Publication of NO982696L publication Critical patent/NO982696L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/24—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings
    • C07C225/26—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings
    • C07C225/30—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings of condensed quinone ring systems formed by two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C46/00—Preparation of quinones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/24—Quinones containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
    • C07C50/32—Quinones containing groups having oxygen atoms singly bound to carbon atoms the quinoid structure being part of a condensed ring system having two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/60—Naphthoxazoles; Hydrogenated naphthoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/84—Naphthothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/12—One of the condensed rings being a six-membered aromatic ring the other ring being at least seven-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Foreliggende oppfinnelse angår den terapeutisk anvendelsen av tricykliske forbindelser og deres farmasøytisk godtagbare salter som har den generelle formelen: hvor: A er enten et svovelatom, et oksygenatom eller et R3N-radikal hvor R3 er et hydrogenatom, et Ci-C5-alkyl-radikal, eller en substituert eller usubstituert aroma-tisk ring, eller en substituert eller usubstituert heteroaromatisk ring. R! er enten et d-Cs-alkyl-radikal, eller et R4NH-radikal hvor Fl* er et hydrogen- atom, et Ci-C5-alkyl-radikal, eller en substituert eller usubstituert aromatisk ring, eller en substituert eller usubstituert heteroaromatisk ring, eller en aromatisk ring som kan være substituert med en eller flere akseptor- eller donorgrupper eller ikke, eller en hetero- aromatisk ring som har en eller flere heteroatomer, som kan være substituert med akseptor- eller donorgrupper eller ikke. R2 er et hydrogenatom, halogenatom, et CrC5-alkyl-radikal, et oksygenatom som kan være substituert med et Ci-C5-alkyl-radikal eller ikke, eller et NRsRs-radikal hvor R5 og Ry er, uavhengig av hverandre, et hydrogen-atom, et oksygenatom eller mono- valente Ci-Cs-organiske radikaler.
NO982696A 1995-12-12 1998-06-11 Anvendelse av tricykliske derivater av 1,4-dihydro-1,4-diokso-1H-naftalen, nye oppnÕdde forbindelser og deres applikasjon i terapi NO982696L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9514683A FR2742153B1 (fr) 1995-12-12 1995-12-12 Utilisation de derives tricycliques du 1,4-dihydro-1,4- dioxo-1h-naphtalene, nouveaux composes obtenus et leur application en therapeutique
PCT/FR1996/001973 WO1997021684A1 (fr) 1995-12-12 1996-12-10 Utilisation de derives tricycliques du 1,4-dihydro-1,4-dioxo-1h-naphtalene, nouveaux composes obtenus et leur application en therapeutique

Publications (2)

Publication Number Publication Date
NO982696D0 NO982696D0 (no) 1998-06-11
NO982696L true NO982696L (no) 1998-08-11

Family

ID=9485393

Family Applications (1)

Application Number Title Priority Date Filing Date
NO982696A NO982696L (no) 1995-12-12 1998-06-11 Anvendelse av tricykliske derivater av 1,4-dihydro-1,4-diokso-1H-naftalen, nye oppnÕdde forbindelser og deres applikasjon i terapi

Country Status (26)

Country Link
US (1) US6262095B1 (no)
EP (1) EP0876356B1 (no)
JP (1) JP2000501724A (no)
KR (1) KR19990072080A (no)
AP (1) AP889A (no)
AR (1) AR005054A1 (no)
AT (1) ATE207907T1 (no)
AU (1) AU716199B2 (no)
BR (1) BR9611935A (no)
CA (1) CA2240279A1 (no)
CZ (1) CZ181198A3 (no)
DE (1) DE69616598D1 (no)
EE (1) EE9800174A (no)
FR (1) FR2742153B1 (no)
HU (1) HUP9901247A3 (no)
ID (1) ID16081A (no)
IL (1) IL124558A0 (no)
LT (1) LT4491B (no)
LV (1) LV12188B (no)
NO (1) NO982696L (no)
NZ (1) NZ323967A (no)
OA (1) OA10696A (no)
PL (1) PL327168A1 (no)
RU (1) RU2178791C2 (no)
TR (1) TR199801069T2 (no)
WO (1) WO1997021684A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032115A1 (en) * 1997-12-19 1999-07-01 Advanced Research And Technology Institute, Inc. Modulators of ryanodine receptors comprising 2-(aryl)-4,7-dioxobenzothiazoles and analogues thereof
AU3113902A (en) * 2000-12-21 2002-07-01 Bristol Myers Squibb Co Thiazolyl inhibitors of tec family tyrosine kinases
AR061478A1 (es) * 2006-06-19 2008-08-27 Takeda Pharmaceutical Compuesto triciclico y composicion farmaceutica
WO2007149484A2 (en) 2006-06-20 2007-12-27 Dana-Farber Cancer Institute Inhibitors of usp1 deubiquitinating enzyme complex
CA2797719C (en) 2010-04-30 2019-11-26 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of usp1 deubiquitinating enzyme activity
US9040713B2 (en) * 2010-09-27 2015-05-26 Emory University Methods of managing blood sugar levels and compositions related thereto
US9725425B1 (en) 2014-02-25 2017-08-08 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
RU2545091C1 (ru) * 2014-03-18 2015-03-27 Федеральное государственное бюджетное учреждение "Российский онкологический научный центр имени Н.Н. Блохина" Российской академии медицинских наук (ФГБУ "РОНЦ им. Н.Н. Блохина" РАМН) 1-R-4,9-ДИОКСО-1H-НАФТО[2,3-d][1,2,3]ТРИАЗОЛ-4-ОКСИМ-2-ОКСИДЫ И ИХ ПРОИЗВОДНЫЕ, ОБЛАДАЮЩИЕ ЦИТОТОКСИЧЕСКОЙ АКТИВНОСТЬЮ
US10829427B2 (en) 2015-12-18 2020-11-10 The Board Of Regents Of The University Of Texas System Naphthoquinones, pro-drugs, and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3039925A (en) 1957-04-24 1962-06-19 Bayer Ag Compositions for the treatment of tuberculosis
US4746676A (en) 1984-09-12 1988-05-24 Rorer Pharmaceutical Corporation Carboxyalkyl dipeptide compounds
JPH05112533A (ja) * 1991-05-08 1993-05-07 Upjohn Co:The イミダゾベンゾキノン類およびこれを有効成分とする高血圧・鬱血性心不全の予防・治療剤

Also Published As

Publication number Publication date
AU1101897A (en) 1997-07-03
AP889A (en) 2000-11-17
CA2240279A1 (fr) 1997-06-19
NZ323967A (en) 2000-06-23
US6262095B1 (en) 2001-07-17
EP0876356A1 (fr) 1998-11-11
EE9800174A (et) 1998-12-15
FR2742153B1 (fr) 1998-02-13
RU2178791C2 (ru) 2002-01-27
TR199801069T2 (xx) 1998-08-21
HUP9901247A3 (en) 2000-08-28
FR2742153A1 (fr) 1997-06-13
PL327168A1 (en) 1998-11-23
KR19990072080A (ko) 1999-09-27
AR005054A1 (es) 1999-04-07
ATE207907T1 (de) 2001-11-15
LV12188A (lv) 1998-12-20
DE69616598D1 (de) 2001-12-06
LT98085A (en) 1998-11-25
AU716199B2 (en) 2000-02-24
BR9611935A (pt) 1999-05-18
LV12188B (en) 1999-07-20
EP0876356B1 (fr) 2001-10-31
HUP9901247A2 (hu) 1999-08-30
ID16081A (id) 1997-09-04
JP2000501724A (ja) 2000-02-15
WO1997021684A1 (fr) 1997-06-19
LT4491B (lt) 1999-04-26
AP9801275A0 (en) 1998-06-30
NO982696D0 (no) 1998-06-11
CZ181198A3 (cs) 1998-09-16
OA10696A (fr) 2002-11-26
IL124558A0 (en) 1998-12-06

Similar Documents

Publication Publication Date Title
ATE283268T1 (de) 2-adamantylethylamine und deren verwendung bei der behandlung von abnormalitäten in der glutamat transmission
NO900336D0 (no) Fremgangsmaate til fremstilling av heterocykliske forbindelser.
NO933434L (no) Piperidinderivater, deres fremstilling og anvendelse
NO994452L (no) Substituerte 4-arylmetylen-2-imino-2,3-dihydrotiazoler og derivater, og deres farmasöytiske anvendelse
NO941101D0 (no) Quinazolin-derivater
DK0944617T3 (da) Krystaller af benzimidazolderivater og deres fremstilling
NO922940L (no) Fem-leddete heterocykliske forbindelser, fremgangsmaate for deres fremstilling og legemidler inneholdende dem
MY101208A (en) Phenyl-piperazine anti-arrhythmia agents.
DE3881472T2 (de) Heterocyclische Verbindungen mit therapeutischer Wirkung.
NO982696L (no) Anvendelse av tricykliske derivater av 1,4-dihydro-1,4-diokso-1H-naftalen, nye oppnÕdde forbindelser og deres applikasjon i terapi
DK0565377T3 (da) Terapeutiske midler til behandling af Parkinsons sygdom
NO20003773L (no) Syklobutenderivater, deres fremstilling og deres terapeutiske anvendelser
NZ314570A (en) Treatment of emesis using tetrahydrobenz[cd]indole-6-carboxamides
NO933435L (no) Piperidinderivater, deres fremstilling og anvendelse
DE60009868T2 (de) Anti-tumor dihydrochinazolindervate
NO934227L (no) Pyrrolderivater, fremgangsmåte for deres fremstilling og terapeutiske anvendelse
ATE200491T1 (de) 2-aminoalkyl-5-aminoalkylamino substituierte isochinoindazole-6 (2h)-on mit antitumorwirkung
DE69706355D1 (de) Alkylendiamin-Derivate als Arzneimittel zur Behandlung von Geschwüren und Hemmung von Helicobacter pylori
NO893039L (no) Bruk av imidazopyrazol-derivater som analgesiske og antiinflammatoriske midler.
NO975811L (no) Ny anvendelse for pyrrolderivater
NO20012538L (no) Anvendelse av N-substituerte azabicycloalkanderivater for behandling av forstyrrelser i sentralnervesystemet
DE3782235T2 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur prophylaxe und zur behandlung von herzinsuffizienz.
DE69129203T2 (de) Verwendung von pyridine derivate zur behandlung der okulären hypertomie
DE60008503D1 (de) Herstellung von chiralen cis-5-amino-2-cyclopenten-1-ol derivaten
MY103817A (en) Chloroaniline derivatives

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application